Professor Claude Wischik, co-founder and CEO of TauRx and Dr. Serge Gauthier, Chairman of TauRx scientific advisory board and director of the Alzheimer's Disease Research Unit, McGill Centre for Studies in Ageing, Quebec, Canada discuss the LUCIDITY enrolment completion and the future of tau focussed therapies. Visit www.taurx.com to find out more.

свернуть